(Q48220675)

9 February 2018

title

Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors. (English)

1 reference

9 February 2018

0 references

C A Kruse

1

1 reference

9 February 2018

P M Schiltz

2

1 reference

9 February 2018

D Bellgrau

3

1 reference

9 February 2018

Q Kong

4

1 reference

9 February 2018

B K Kleinschmidt-DeMasters

5

1 reference

9 February 2018

publication date

1 January 1994

1 reference

9 February 2018

Journal of Neuro-Oncology

published in

1 reference

9 February 2018

volume

19

1 reference

9 February 2018

page(s)

161-168

1 reference

9 February 2018

issue

2

1 reference

9 February 2018

https://scigraph.springernature.com/pub.10.1007/bf01306458

exact match

0 references

cites work

Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma.

1 reference

12 December 2020

Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro

1 reference

12 December 2020

Activation and adhesion molecule expression on lymphoid infiltrates in human glioblastomas.

1 reference

12 December 2020

Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement.

1 reference

12 December 2020

Allogeneic tumor-specific cytotoxic T lymphocytes

1 reference

12 December 2020

Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin.

1 reference

12 December 2020

In vitro studies on the cell-mediated immune response to human brain tumors. I. Requirement for third-party stimulator lymphocytes in the induction of cell-mediated cytotoxic responses to allogeneic cultured gliomas

1 reference

12 December 2020

Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects.

1 reference

12 December 2020

Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy

1 reference

12 December 2020

Quantitative appraisal of H-2 products in T cell-mediated lysis by allogeneic and syngeneic effector cells

1 reference

12 December 2020

Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses

1 reference

12 December 2020

Lymphoid cell-glioma cell interaction enhances cell coat production by human gliomas: novel suppressor mechanism.

1 reference

12 December 2020

Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take

1 reference

12 December 2020

Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations

1 reference

12 December 2020

Heterogeneity of Genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas.

1 reference

12 December 2020

The cellular immunotherapy of primary brain tumors

1 reference

12 December 2020

A 9L gliosarcoma transplantation model for studying adoptive immunotherapy into the brains of conscious rats

1 reference

12 December 2020

Adjuvant adoptive immunotherapy for pediatric recurrent brain tumors

1 reference

12 December 2020

Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01306458

1 reference

9 February 2018

PubMed ID

7964992

1 reference

9 February 2018